Ad www.ProStocks.com
FREE Account Opening + No Clearing Fees + Rs 999 API Access
|
|
| Issue Open | Sep 29, 2017 |
| Issue Close | Oct 4, 2017 |
| IPO Price | ₹85 |
| Face Value | ₹10 |
| IPO Size | ₹19.52 Cr |
| Listing At | NSE SME |
| IPO Lot Size | 1600 |
Mon, 10 Jan 2022 03:27:00 GMT
It went public in an upsized IPO in early 2020 and ... Its most advanced drug candidate, for sickle-cell disease and beta thalassemia, is expected to enter Phase 1 clinical trials this year.
Thu, 06 Jan 2022 16:00:00 GMT
In its prospectus, Alector challenges longstanding theories that point to problem proteins—amyloid beta and tau ... the dose of the drug. The company plans use the IPO proceeds to move on ...
Thu, 20 Jan 2022 11:47:00 GMT
Despite this, European stocks enter 2022 as a beloved asset class among Wall Street strategists, who say the region is a hotbed of value-priced opportunity. As of the start of the year, the Stoxx ...
Mon, 10 Jan 2022 10:47:00 GMT
Robbins Geller Rudman & Dowd LLP announces that purchasers of Talis Biomedical Corporation common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the ...
Thu, 13 Jan 2022 09:27:00 GMT
As record levels of money pour into gene therapy research, biotechs are under increased pressure to address issues related to safety, delivery and overlapping pipelines.
Fri, 14 Jan 2022 12:55:00 GMT
Thus, for this article, I limit the details on semiconductor manufacturing, market potential, and the pending Mobileye spinoff IPO to the company ... in the space of drugs. The company was founded ...
Tue, 04 Jan 2022 14:10:00 GMT
and Suzhou, China-based company plans to use HK$243.3 million, or about 58% of the proceeds for the development and commercialization for the company’s core product, STP-705, a dual transforming ...
Thu, 13 Jan 2022 08:48:00 GMT
Alzheimer’s Disease (AD) is a feared diagnosis that afflicts many older individuals, particularly women and those with a genetic predisposition for the condition. AD is so frightening in large part ...
Wed, 22 Dec 2021 16:00:00 GMT
Bevrit’s short flight as a billionaire started with the August IPO via SPAC merger of his Santa ... large losses and its struggle to transition into drug development. 23andMe’s shares are ...
Mon, 20 Dec 2021 04:22:00 GMT
Bursa will become a one-stop centre for all ACE Market IPO approvals under the new regulatory framework, including the registration of abridged prospectuses for the purpose of secondary ...
Thu, 06 Jan 2022 00:55:00 GMT
Dr. Fjällskog has over 30 years of experience in clinical oncology, translational research, and drug development ... in Sensei's successful $152 million IPO, which closed in February 2021.
The issue of Beta Drugs Limited opens on Sep 29, 2017 and closes for subscription on Oct 04, 2017. The equity shares of the company to be list at NSE SME. The price band for the issue has been fixed at Rs 85.
Beta Drugs Limited is entering in the capital market with an IPO of 229,600 Equity Shares of Rs 10 aggregating up to Rs 1.95 Cr. The price band for the issue has been fixed at Rs 85.
Beta Drugs Limited is pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers.
The issue opens on Sep 29, 2017 and closes for subscription on Oct 4, 2017. The equity shares of the company to be list at NSE SME platform.
The Beta Drugs IPO is proposed to open on Sep 29, 2017. The IPO application ends on Oct 4, 2017.
Retail investors can apply in the retail or non-institutional investor category from Sep 29, 2017 to Oct 4, 2017. The Beta Drugs IPO can be applied online through Net Bank (ASBA method) or the stock broker (UPI method).
The Beta Drugs IPO will open for subscription on Sep 29, 2017. The public issue will close on Oct 4, 2017.
Useful Articles
